Cost-Effectiveness of Minimally Invasive Esophagectomy for Esophageal Squamous Cell Carcinoma
- PMID: 29380008
- DOI: 10.1007/s00268-018-4501-5
Cost-Effectiveness of Minimally Invasive Esophagectomy for Esophageal Squamous Cell Carcinoma
Abstract
Introduction: The cost-effectiveness of minimally invasive esophagectomy (MIE) versus open esophagectomy (OE) for esophageal squamous cell carcinoma (ESCC) has not been established. Recent cost studies have shown that MIE is associated with a higher surgical expense, which is not consistently offset by savings through expedited post-operative recovery, therefore suggesting a questionable benefit of MIE over OE from an economic point of view. In the current study, we compared the cost-effectiveness of MIE versus OE for ESCC.
Materials and methods: Between April 2000 and December 2013, a total of 251 consecutive patients undergoing MIE or OE for ESCC were enrolled. After propensity score (PS)-matching the MIE group with the OE group for clinical characteristics, 95 patients from each group were enrolled to compare the peri-operative outcomes, long-term survival, and cost.
Results: After PS-matching, the baseline characteristics were not significantly different between groups. Perioperative outcomes were similar in both groups. MIE was superior to OE with respect to a shorter intensive care unit (ICU) stay, while the complication rate (except for hoarseness) and survival were similar. Post-operative cost was significantly less in the MIE group due to a shorter ICU stay; however, reduced post-operative cost failed to offset the higher surgical expense of MIE.
Conclusions: MIE for ESCC failed to show cost-effectiveness regarding overall expense in our study, but costs less in the postoperative care, especially for ICU care. More cost studies on MIE in other health care systems are warranted to verify the cost-effectiveness of MIE.
Similar articles
-
Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: A propensity score-matched comparison of operative approaches.J Thorac Cardiovasc Surg. 2015 Apr;149(4):1006-14; discussion 1014- 5.e4. doi: 10.1016/j.jtcvs.2014.12.063. Epub 2015 Jan 9. J Thorac Cardiovasc Surg. 2015. PMID: 25752374
-
Impact of surgical approach on perioperative and long-term outcomes following esophagectomy for esophageal cancer.Surg Endosc. 2018 Apr;32(4):1892-1900. doi: 10.1007/s00464-017-5881-6. Epub 2017 Oct 24. Surg Endosc. 2018. PMID: 29067584
-
Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis.Surg Endosc. 2018 Nov;32(11):4443-4450. doi: 10.1007/s00464-018-6187-z. Epub 2018 Apr 11. Surg Endosc. 2018. PMID: 29644466
-
Current status of minimally invasive esophagectomy for patients with esophageal cancer.Gen Thorac Cardiovasc Surg. 2013 Sep;61(9):513-21. doi: 10.1007/s11748-013-0258-9. Epub 2013 May 10. Gen Thorac Cardiovasc Surg. 2013. PMID: 23661109 Review.
-
Recent advances in thoracoscopic esophagectomy for esophageal cancer.Asian J Endosc Surg. 2019 Jan;12(1):19-29. doi: 10.1111/ases.12681. Epub 2018 Dec 27. Asian J Endosc Surg. 2019. PMID: 30590876 Review.
Cited by
-
Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.Ann Transl Med. 2021 Aug;9(15):1226. doi: 10.21037/atm-21-1803. Ann Transl Med. 2021. PMID: 34532363 Free PMC article.
-
Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.Front Public Health. 2022 Jun 29;10:923619. doi: 10.3389/fpubh.2022.923619. eCollection 2022. Front Public Health. 2022. PMID: 35844891 Free PMC article.
-
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.Front Oncol. 2021 Dec 1;11:790373. doi: 10.3389/fonc.2021.790373. eCollection 2021. Front Oncol. 2021. PMID: 34926306 Free PMC article.
-
Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.Adv Ther. 2023 Mar;40(3):1019-1030. doi: 10.1007/s12325-022-02402-z. Epub 2023 Jan 9. Adv Ther. 2023. PMID: 36622553
-
Minimally invasive techniques for transthoracic oesophagectomy for oesophageal cancer: systematic review and network meta-analysis.BJS Open. 2020 Oct;4(5):787-803. doi: 10.1002/bjs5.50330. Epub 2020 Sep 7. BJS Open. 2020. PMID: 32894001 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous